분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-11-21 13:26:10 , Hit : 1126
 Cost to Develop a Drug More Than Doubles to $2.56 Billion


By Anna Edney Nov 19, 2014 12:30 AM GMT+0900Email Print Speed

  It costs drugmakers $2.56 billion to bring a new medicine to market, on average, more than double the price of 11 years ago, according to a study released today.

The higher cost comes from clinical trials that are larger and more complex, as well as more drugs that fail in development, according to the researchers. While the Food and Drug Administration is sometimes blamed for driving up costs because of the time it takes to review new drugs, that wasn’t a factor, according to the study by the Tufts Center for the Study of Drug Development.

“Drug development remains a costly undertaking despite ongoing efforts across the full spectrum of pharmaceutical and biotech companies to rein in growing R&D costs,” Joseph DiMasi, director of economic analysis at the Boston-based center, said in a statement.

Drug and biotechnology companies have come under pressure from lawmakers and health insurance companies to justify the costs of of their products. It’s a long-running debate that’s been reignited with the introduction of treatments like Gilead Sciences Inc.’s hepatitis C pill, Harvoni, which costs $94,500 for a 12-week course. The new drugs are the product of breakthrough science -- and come with breakthrough price tags.

As of the Tufts Center’s last estimate, in 2003, it cost $1.04 billion in 2013 dollars to develop a new brand-name drug. About 40 percent of the center’s funding comes from drug companies, with the rest from research grants and educational course fees.

Industry Attack
The health insurance lobby has repeatedly attacked the drug industry’s prices. America’s Health Insurance Plans, the industry’s Washington-based trade group, sends out weekly, if not daily, e-mails slamming drugmakers for relying on development costs to back the high price of pharmaceuticals.

“It’s become increasingly clear that drug prices are no longer driven by development costs,” Brendan Buck, a spokesman for AHIP, said in a Nov. 17 e-mail. “They’re set by whatever the drugmakers think they can get away with.”

Drugmakers have fired back that drug treatments are often cheaper than surgery or hospital care patients can require without them, and point out that other health-care spending makes up a far bigger part of costs.

The Tufts Center for the Study of Drug Development based its finding on data from the experiences of 10 drug companies and 106 experimental products. Eighty-seven of the products were less complex chemical drugs; the rest were more complex biologic drugs that are manufactured from living organisms.

The costs of development don’t always end after a drug is approved. The FDA can require new studies to get more data on safety and effectiveness, or the drugmaker can conduct trials to expand use of the medicine. Those post-approval studies add $312 million to a drug’s cost, raising the development price tag to $2.87 billion, according to the study.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net

To contact the editors responsible for this story: Crayton Harrison at tharrison5@bloomberg.net Drew Armstrong, John Lear


Press spacebar to pause and continue. Press esc to stop.







987   인간과 생쥐 유전체의 유사성과 차이점  이성욱 2014/11/25 1921
  Cost to Develop a Drug More Than Doubles to $2.56 Billion  이성욱 2014/11/21 1126
985   세균과 싸우도록 자극하면, 바이러스까지도 물리치는 세포  이성욱 2014/11/20 1491
984   Gilead wins European approval of next-generation hepatitis C drug  이성욱 2014/11/20 1159
983   [바이오토픽] 표준 인간 게놈지도의 갭을 메워라: 플래티넘 게놈지도 탄생  이성욱 2014/11/19 1592
982   종양 내에서 T 세포 면역에 핵심적인 항원제시 세포  이성욱 2014/11/17 1657
981   AbbVie, Enanta drug shows potential in hep C genotype 4 patients  이성욱 2014/11/15 1185
980   Gilead hepatitis C drug highly effective in cirrhosis patients  이성욱 2014/11/14 1065
979   새로운 HIV/AIDS 치료법 개발  이성욱 2014/11/14 1467
978   간 이식 환자들의 C형 간염을 완치시킨 새로운 치료법  이성욱 2014/11/14 1663
977   간 이식 환자들의 C형 간염에 효과적인 병용 요법  이성욱 2014/11/13 1606
976   J&J Wins U.S. Approval for Hepatitis C Combo With Gilead  이성욱 2014/11/07 1522
975   에볼라에 대한 반응과 유전적 요인  이성욱 2014/11/04 1278
974   실험실에서 만든 인공위장  이성욱 2014/11/04 1220
973   거울이미지 RNA효소와 생명이 기원  이성욱 2014/11/03 1491
972   어떻게 복잡한 생명은 진화했는가?  이성욱 2014/10/31 1601
971   인간 녹아웃을 연구하는 유전학자들  이성욱 2014/10/31 1561
970   As the RNA World Turns (Either Way, with Cross-Chiral Enzyme)  이성욱 2014/10/31 1346
969   암의 우군-엑소좀(exosome)  이성욱 2014/10/29 2787
968   이웃의 정상세포를 감염시키는 암세포  이성욱 2014/10/27 1464

[이전 10개] [1]..[11][12][13][14] 15 [16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN